Hiller, J. G. et al. Perioperative events influence cancer recurrence risk after surgery. Nat. Rev. Clin. Oncol. 15, 205–218 (2018).
Reya, T. et al. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
Barbato, L. et al. Cancer stem cells and targeting strategies. Cells 8, 926 (2019).
Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124–1134 (2017).
Prager, B. C. et al. Cancer stem cells: the architects of the tumor ecosystem. Cell Stem Cell 24, 41–53 (2019).
Chu, X. et al. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct. Target Ther. 9, 170 (2024).
Gilboa, E. The promise of cancer vaccines. Nat. Rev. Cancer 4, 401–411 (2004).
Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).
Ruiu, R. et al. Cancer stem cell immunology and immunotherapy: harnessing the immune system against cancer’s source. Prog. Mol. Biol. Transl. Sci. 164, 119–188 (2019).
Ning, N. et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 72, 1853–1864 (2012).
Hu, Y. et al. Therapeutic efficacy of cancer stem cell vaccines in the adjuvant setting. Cancer Res. 76, 4661–4672 (2016).
Klein, O. et al. Melanoma vaccines: developments over the past 10 years. Expert Rev. Vaccines 10, 853–873 (2011).
Quaglino, E., Conti, L. & Cavallo, F. Breast cancer stem cell antigens as targets for immunotherapy. Semin. Immunol. 47, 101386 (2020).
Hassani, N. A. et al. Cancer immunotherapy via targeting cancer stem cells using vaccine nanodiscs. Nano Lett. 20, 7783–7792 (2020).
Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555–567 (2007).
Silva, I. A. et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 71, 3991–4001 (2011).
Wang, Q. et al. Tamoxifen enhances stemness and promotes metastasis of ERα36+ breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 28, 336–358 (2018).
Liu, C. et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression. Cancer Res. 81, 5919–5934 (2021).
Lizee, G. et al. Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. Nat. Immunol. 4, 1065–1073 (2003).
Samie, M. & Cresswell, P. The transcription factor TFEB acts as a molecular switch that regulates exogenous antigen-presentation pathways. Nat. Immunol. 16, 729–736 (2015).
Han, D. et al. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 566, 270–274 (2019).
Min, L. H. Cationic lipids-mediated dual-targeting of both dendritic cells and tumor cells for potent cancer immunotherapy. Adv. Funct. Mater. 33, 2306752 (2023).
Hu, M. et al. Immunogenic hybrid nanovesicles of liposomes and tumor-derived nanovesicles for cancer immunochemotherapy. ACS Nano 15, 3123–3138 (2021).
Gabrilovich, D. I., Ostrand, R. S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253–268 (2012).
Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462 (2016).
Xiao, Z., Todd, L. & Huang, L. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat. Commun. 14, 510 (2023).
Lakins, M. A., Ghorani, E. & Munir, H. Cancer-associated fibroblasts induce antigen-specific deletion of CD8+ T cells to protect tumour cells. Nat. Commun. 9, 948 (2018).
Hong, J. et al. T‐cell‐derived nanovesicles for cancer immunotherapy. Adv. Mater. 33, 2101110 (2021).
Trevaskis, N. L., Kaminskas, L. M. & Porter, C. J. From sewer to saviour—targeting the lymphatic system to promote drug exposure and activity. Nat. Rev. Drug. Discov. 14, 781–803 (2015).
Chen, L. et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci. Transl. Med. 13, 601 (2021).
von Andrian, U. H. & Mempel, T. R. Homing and cellular traffic in lymph nodes. Nat. Rev. Immunol. 3, 867–878 (2003).
Clatworthy, M. R. et al. Immune complexes stimulate CCR7-dependent dendritic cell migration to lymph nodes. Nat. Med. 20, 1458–1463 (2014).
Lin, W. et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat. Commun. 14, 265 (2023).
You, Q. et al. m6A reader YTHDF1-targeting engineered small extracellular vesicles for gastric cancer therapy via epigenetic and immune regulation. Adv. Mater. 35, e2204910 (2023).
Cui, C. et al. A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours. Nat. Nanotechnol. 16, 1394–1402 (2021).
Zehner, M. et al. The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8+ T cells. Immunity 42, 850–863 (2015).
McClements, L. et al. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin. Cancer Res. 19, 3881–3893 (2013).
Shen, S. et al. A nanotherapeutic strategy to overcome chemotherapeutic resistance of cancer stem-like cells. Nat. Nanotechnol. 16, 104–113 (2021).
Dieter, S. M. et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9, 357–365 (2011).
Zhang, W. C. et al. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat. Commun. 7, 11702 (2016).
Nguyen, L. N. M. et al. The exit of nanoparticles from solid tumours. Nat. Mater. 22, 1261–1272 (2023).
Fu, A. et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell 185, 1356–1372 (2022).
Wang, K. Biomimetic nanovaccine-mediated multivalent IL-15 self-transpresentation (MIST) for potent and safe cancer immunotherapy. Nat. Commun. 14, 6748 (2023).
Zhai, Y. et al. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. Nat. Nanotechnol. 16, 1271–1280 (2021).
Krishnan, N. et al. A modular approach to enhancing cell membrane-coated nanoparticle functionality using genetic engineering. Nat. Nanotechnol. 19, 345–353 (2024).
Elsadek, B. & Kratz, F. Impact of albumin on drug delivery-new applications on the horizon. J. Control. Release 157, 4–28 (2012).
Song, Y. et al. Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice. Sci. Transl. Med. 14, eabl3649 (2022).
Zhang, S. et al. Type 1 conventional dendritic cell fate and function are controlled by DC-SCRIPT. Sci. Immunol. 6, eabf4432 (2021).
Giampazolias, E. et al. Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity. Cell 184, 4016–4031. e22 (2021).
Canton, J. et al. The receptor DNGR-1 signals for phagosomal rupture to promote cross-presentation of dead-cell-associated antigens. Nat. Immunol. 22, 140–153 (2021).
Roney, K. Bone marrow-derived dendritic cells. Methods Mol. Biol. 1960, 57–62 (2019).
Assouvie, A., Daley-Bauer, L. P. & Rousselet, G. Growing murine bone marrow-derived macrophages. Methods Mol. Biol. 1784, 29–33 (2018).
Hui, Y. et al. Selection of DNA aptamers against DC-SIGN protein. Mol. Cell. Biochem. 306, 71–77 (2007).
Ghosh, M. & Shapiro, L. H. In vitro Ag cross-presentation and in vivo Ag cross-presentation by dendritic cells in the mouse. Bio-Protocol 2, e305 (2012).
Liu, C. et al. A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy. Nat. Nanotechnol. 17, 531–540 (2022).
